If you tried to play a drinking game with the number of times I've mentioned consistency and/or execution in relation to GenMark Diagnostics (GNMK),
you would risk serious damage to your liver. Even so, the ability of
this company to deliver on the promise of its ePlex multiplex diagnostic
system is arguably the key variable in the entire investment equation.
The question of whether or not multiplex testing delivers value for
health care systems is more or less settled, but whether GenMark can
generate adequate commercial interest in its system, manufacture them
profitably, and develop an adequate test menu in time are not settled.
With
good flu-related demand in the first quarter and the recent submission
of the gram-positive sepsis to the FDA, I think things are looking
better for GenMark, and the shares are up about 50% from last update in
March. If management continues to deliver, this could only be the
beginning, as GenMark serves a market that can support hundreds of
millions of dollars in revenue at better multiples than the shares
currently enjoy.
Read more here :
GenMark Diagnostics Starting To Deliver, But Consistency Is A Key Issue
No comments:
Post a Comment